[HTML][HTML] ESMO expert consensus statements (ECS) on the definition, diagnosis, and management of HER2-low breast cancer
P Tarantino, G Viale, MF Press, X Hu… - Annals of …, 2023 - Elsevier
Human epidermal growth factor receptor 2 (HER2)-low breast cancer has recently emerged
as a targetable subset of breast tumors, based on the evidence from clinical trials of novel …
as a targetable subset of breast tumors, based on the evidence from clinical trials of novel …
Standardized pathology report for HER2 testing in compliance with 2023 ASCO/CAP updates and 2023 ESMO consensus statements on HER2-low breast cancer
Since the release of the DESTINY-Breast04 (DB-04) trial findings in June 2022, the field of
pathology has seen a renaissance of HER2 as a predictive biomarker in breast cancer. The …
pathology has seen a renaissance of HER2 as a predictive biomarker in breast cancer. The …
Human epidermal growth factor receptor 2 testing in breast cancer: ASCO–College of American Pathologists Guideline Update
AC Wolff, MR Somerfield, M Dowsett… - Journal of Clinical …, 2023 - ascopubs.org
PURPOSE To update ASCO–College of American Pathologists (CAP) recommendations for
human epidermal growth factor receptor 2 (HER2) testing in breast cancer. The Panel is …
human epidermal growth factor receptor 2 (HER2) testing in breast cancer. The Panel is …
Clinicopathologic characteristics and prognosis of ERBB2-low breast cancer among patients in the national cancer database
Importance Given conflicting results regarding the prognosis of erb-b2 receptor tyrosine
kinase 2 (ERBB2; formerly HER2 or HER2/neu)–low breast cancer, a large-scale, nationally …
kinase 2 (ERBB2; formerly HER2 or HER2/neu)–low breast cancer, a large-scale, nationally …
Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology–College of American Pathologists Guideline Update
AC Wolff, MR Somerfield, M Dowsett… - … of pathology & …, 2023 - meridian.allenpress.com
Purpose.—To update the American Society of Clinical Oncology–College of American
Pathologists (ASCO-CAP) recommendations for human epidermal growth factor receptor 2 …
Pathologists (ASCO-CAP) recommendations for human epidermal growth factor receptor 2 …
Comprehensive genomic characterization of HER2-low and HER2-0 breast cancer
P Tarantino, H Gupta, ME Hughes, J Files… - nature …, 2023 - nature.com
The molecular underpinnings of HER2-low and HER2-0 (IHC 0) breast tumors remain poorly
defined. Using genomic findings from 1039 patients with HER2-negative metastatic breast …
defined. Using genomic findings from 1039 patients with HER2-negative metastatic breast …
Comparison of HER2-zero and HER2-low in terms of clinicopathological factors and survival in early-stage breast cancer: A systematic review and meta-analysis
Background The prognostic differences between HER2-zero and HER2-low breast cancer
(BC) remain unclear. Purpose of this meta-analysis is to investigate the differences between …
(BC) remain unclear. Purpose of this meta-analysis is to investigate the differences between …
[HTML][HTML] Prognostic value of HER2-low status in breast cancer: a systematic review and meta-analysis
C Molinelli, F Jacobs, E Agostinetto, G Nader-Marta… - ESMO open, 2023 - Elsevier
Background Human epidermal growth factor receptor 2 (HER2)-low expression in breast
cancer has been recently identified as a new therapeutic target. However, it is unclear if …
cancer has been recently identified as a new therapeutic target. However, it is unclear if …
[HTML][HTML] Clinical implications of the intrinsic molecular subtypes in hormone receptor-positive and HER2-negative metastatic breast cancer
C Falato, F Schettini, T Pascual… - Cancer Treatment …, 2023 - Elsevier
Traditionally, the classification of breast cancer relies on the expression of
immunohistochemical (IHC) biomarkers readily available in clinical practice. Using highly …
immunohistochemical (IHC) biomarkers readily available in clinical practice. Using highly …
Current biological, pathological and clinical landscape of HER2-low breast cancer
H Zhang, Y Peng - Cancers, 2022 - mdpi.com
Simple Summary The breakthrough in develo** novel HER2-targeting antibody drug
conjugates and identifying their clinical benefits in HER2-low breast cancer will dramatically …
conjugates and identifying their clinical benefits in HER2-low breast cancer will dramatically …